Percent of all randomized patients who achieved CID at any visit, elapsed time to the first occurrence, and total time spent in CID, by initial treatment arm.
| Baseline Treatment | MEPb, n = 42 | MTXc, n = 43 | Total, n = 85 | pa |
|---|---|---|---|---|
| No. (%) achieving CID | 30 (71.4) | 28 (65.1) | 58 (68.2) | 0.64 |
| No. (%) not achieving CID | 12 (28.6) | 15 (34.9) | 27 (31.8) | |
| Days to first observation in CID | ||||
| Median | 168.5 | 192 | 175 | 1 |
| Mean (SD) | 187 (89) | 199 (85) | 193 (86) | |
| Min–Max | 29–340 | 56–346 | 29–346 | |
| Total days of observation in CID | ||||
| Median | 139.5 | 79 | 108.5 | 0.048 |
| Mean (SD) | 124 (73) | 92 (65) | 109 (71) | |
| Min–Max | 1–270 | 1–229 | 1–270 | |
| Percent of total days of observation in CID | ||||
| Median | 42 | 24.8 | 34.1 | 0.7 |
| Mean (SD) | 38 (22) | 33 (24) | 36 (23) | |
| Min–Max | 0.3–81.6 | 0.3–89.1 | 0.3–89.1 |
↵a p values (family-wise Bonferroni corrected) based on Mann-Whitney U test and refer to the comparison between MEP and MTX;
↵b Methotrexate, blind etanercept, blind prednisolone tapered to zero by 17 weeks;
↵c Methotrexate, blind placebo etanercept, blind placebo prednisolone. CID: clinically inactive disease.